Delcath Systems (NASDAQ:DCTH) Announces Quarterly Earnings Results

Delcath Systems (NASDAQ:DCTH) posted its earnings results on Thursday. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.16, FiscalAI reports. The company had revenue of $29.13 million for the quarter, compared to analyst estimates of $26.25 million. Delcath Systems had a return on equity of 0.47% and a net margin of 0.56%.

Here are the key takeaways from Delcath Systems’ conference call:

• HEPZATO revenue and guidance increased: Second-quarter HEPZATO KIT revenue reached $27.1 million, up 21% year over year, while volume rose 30% despite the impact of 340B pricing. Delcath raised full-year 2026 revenue guidance to $104 million-$108 million and expects positive adjusted EBITDA.
• Commercial footprint continued to expand: The company activated two treatment centers in the quarter, reaching 31, and remains confident it can reach approximately 37 centers by year-end. New patient starts averaged about 0.5 per site per month, with leading NCI- and NCCN-affiliated institutions making up a substantial portion of the network.
• Expansion into additional cancers is progressing but remains early: Phase II studies in third-line liver-dominant colorectal cancer and HER2-negative metastatic breast cancer are adding sites and improving enrollment, while an interim colorectal readout is expected in late 2027. Management acknowledged that enrollment has been slower than initially expected because of the complexity of coordinating oncology and interventional radiology teams.
• Profitability was supported by strong gross margins, but investment and pricing pressures remain: Second-quarter gross margin improved to 90%, although full-year guidance is 86%-89% due partly to anticipated manufacturing costs. Research and development and selling, general and administrative expenses increased year over year, while adjusted EBITDA declined to $7.6 million from $9.8 million.

Delcath Systems Trading Down 2.3%

NASDAQ:DCTH traded down $0.36 during mid-day trading on Friday, hitting $15.11. 1,212,338 shares of the company’s stock traded hands, compared to its average volume of 498,787. The firm has a market capitalization of $521.60 million, a price-to-earnings ratio of 1,512.51 and a beta of 0.52. The firm has a 50 day moving average of $12.35 and a two-hundred day moving average of $10.87. Delcath Systems has a 12 month low of $8.12 and a 12 month high of $16.38.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on DCTH shares. Weiss Ratings raised Delcath Systems from a “sell (d)” rating to a “sell (d+)” rating in a research note on Monday, May 11th. HC Wainwright reaffirmed a “buy” rating and set a $32.00 target price (up from $30.00) on shares of Delcath Systems in a research report on Friday. Wall Street Zen upgraded Delcath Systems from a “hold” rating to a “buy” rating in a report on Saturday. BTIG Research lifted their price target on shares of Delcath Systems from $17.00 to $21.00 and gave the company a “buy” rating in a research report on Thursday. Finally, Zacks Research upgraded shares of Delcath Systems from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 7th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Delcath Systems presently has an average rating of “Moderate Buy” and a consensus price target of $23.17.

Key Delcath Systems News

Here are the key news stories impacting Delcath Systems this week:

• Positive Sentiment: Quarterly earnings beat expectations: Delcath reported second-quarter earnings of $0.07 per share, versus the consensus estimate for a $0.09 loss, while revenue of $29.13 million exceeded expectations of $26.25 million. Earnings matched the year-ago quarter and represent a significant improvement relative to analyst forecasts. MarketBeat earnings report Zacks earnings coverage
• Positive Sentiment: Revenue outlook is above consensus: The company issued fiscal 2026 revenue guidance of $104 million to $108 million, ahead of the approximately $103.3 million analyst consensus. The outlook reinforces expectations for continued commercial growth. Benzinga guidance coverage
• Positive Sentiment: Analyst price target increased: BTIG Research raised its DCTH price target from $17 to $21 and maintained a Buy rating, signaling greater confidence in the company’s growth prospects and implying substantial potential upside from recent trading levels. Benzinga analyst coverage
• Positive Sentiment: Momentum and investor attention increased: Coverage highlighted DCTH’s best trading session in nearly 15 months and a new 52-week high, while volume was more than twice its recent average. These technical signals likely amplified the reaction to the earnings beat. MSN 52-week-high coverage
• Neutral Sentiment: Investors are assessing the earnings-call outlook: Management’s second-quarter conference call focused on operating performance and the updated fiscal 2026 outlook. The guidance is encouraging, although the stock’s valuation remains demanding, with a very high reported price-to-earnings ratio. Seeking Alpha earnings call transcript

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. California State Teachers Retirement System acquired a new stake in shares of Delcath Systems in the second quarter worth $26,000. Russell Investments Group Ltd. acquired a new position in Delcath Systems during the 3rd quarter valued at $29,000. Tower Research Capital LLC TRC bought a new stake in Delcath Systems in the 2nd quarter valued at $40,000. Legal & General Group Plc acquired a new stake in Delcath Systems in the 2nd quarter worth $46,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in Delcath Systems in the 2nd quarter worth $151,000. 61.12% of the stock is currently owned by institutional investors and hedge funds.

About Delcath Systems

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.